Partnership aims to get genomic info to docs for prescribing

Register now

A new initiative seeks to give clinicians access to a database that can inform them on which drugs might be the most effective in treating patient conditions, based on their genetic composition.

The Innovation Institute and 2bPrecise, a wholly owned subsidiary of Allscripts Healthcare Solutions, have announced an agreement that will enable 2bPrecise to deliver a pharmacogenomics knowledge base to the point of care for providers that are members of The Innovation Institute, as well as other providers that aren’t in the networks of those members.

One of the six member owners of the Innovation Institute is Avera Health, which has developed GeneFolio, which describes how drugs and gene tests are related. Insights from the database are intended to be delivered within providers’ workflows, when they are making treatment decisions.

“Pharmacogenomics is poised for rapid healthcare adoption to improve treatment success,” said Krista Bohlen, director of personalized medicine at the Avera Institute for Human Genetics. The GeneFolio capability was “developed by Avera scientists, laboratory personnel and pharmacists.”

GeneFolio uses results from a simple saliva or blood sample and tests multiple genes that impact medications in three main classes—pain, depression and other psychiatric disorders, and statins for cholesterol and certain types of blood thinners. Other classes of use cases are in development. Results are delivered in a color-coded report that shows which medications will be metabolized well by the patient, and which should be used with caution or not used at all. The test can be taken once, and results can be consulted for years to come as other medications are prescribed.

The 2bPrecise platform enables GeneFolio results to be harmonized and delivered to clinicians in an actionable format.

“We can enable physicians to take these insights and order the medications or therapies most likely to be effective with each individual patient. This means improved patient outcomes and a decrease in the overall cost of care,” says Larry Stofko, executive vice president of The Innovation Institute.

The 2bPrecise platform is cloud-based, scalable and EHR-agnostic—it enables clinicians to access genomic insights such as those provided by GeneFolio without leaving their preferred workflows.

For reprint and licensing requests for this article, click here.